"Virus-specific T cells are a good example of that. We've seen increased potency based on the manufacturing and based on improvements to the process. That has allowed us to pivot and deliver those virus-specific T cells in an off-the-shelf fashion. So, now, we're talking about delivery to patients in 48 hours rather than 20 days," Hanley told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.

Hanley, who is ISCT regional vice president-elect, North America, regional executive committee, North America, has helped to pioneer work in expanding virus-specific immune cells from naïve T cells, such as those present in cord blood or virus-seronegative donors and T cells targeting tumor-specific antigens.

Watch the video below to learn more.

ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis,...

ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...

ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...

ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net...

ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...